190 related articles for article (PubMed ID: 37280416)
1. Association Between the Use of Topical Calcineurin Inhibitors and the Risk of Cancer Among Patients with Atopic Dermatitis: A Nationwide, Population-Based, Retrospective Cohort Study.
Huang HH; Shen D; Chan TC; Cho YT; Tang CH; Chu CY
Am J Clin Dermatol; 2023 Sep; 24(5):799-808. PubMed ID: 37280416
[TBL] [Abstract][Full Text] [Related]
2. Association Between Topical Calcineurin Inhibitor Use and Keratinocyte Carcinoma Risk Among Adults With Atopic Dermatitis.
Asgari MM; Tsai AL; Avalos L; Sokil M; Quesenberry CP
JAMA Dermatol; 2020 Oct; 156(10):1066-1073. PubMed ID: 32785626
[TBL] [Abstract][Full Text] [Related]
3. Topical tacrolimus for atopic dermatitis.
Cury Martins J; Martins C; Aoki V; Gois AF; Ishii HA; da Silva EM
Cochrane Database Syst Rev; 2015 Jul; 2015(7):CD009864. PubMed ID: 26132597
[TBL] [Abstract][Full Text] [Related]
4. Systematic review of published trials: long-term safety of topical corticosteroids and topical calcineurin inhibitors in pediatric patients with atopic dermatitis.
Siegfried EC; Jaworski JC; Kaiser JD; Hebert AA
BMC Pediatr; 2016 Jun; 16():75. PubMed ID: 27267134
[TBL] [Abstract][Full Text] [Related]
5. Risk of lymphoma in patients with atopic dermatitis and the role of topical treatment: A systematic review and meta-analysis.
Legendre L; Barnetche T; Mazereeuw-Hautier J; Meyer N; Murrell D; Paul C
J Am Acad Dermatol; 2015 Jun; 72(6):992-1002. PubMed ID: 25840730
[TBL] [Abstract][Full Text] [Related]
6. Association Between Topical Calcineurin Inhibitor Use and Risk of Cancer, Including Lymphoma, Keratinocyte Carcinoma, and Melanoma: A Systematic Review and Meta-analysis.
Lam M; Zhu JW; Tadrous M; Drucker AM
JAMA Dermatol; 2021 May; 157(5):549-558. PubMed ID: 33787818
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of cancer risk related to atopic dermatitis and use of topical calcineurin inhibitors.
Tennis P; Gelfand JM; Rothman KJ
Br J Dermatol; 2011 Sep; 165(3):465-73. PubMed ID: 21466537
[TBL] [Abstract][Full Text] [Related]
8. Topical calcineurin inhibitors and risk of lymphoma: a systematic review and meta-analysis.
Wu PC; Huang IH; Liu CW; Huang YC
J Dtsch Dermatol Ges; 2021 Sep; 19(9):1265-1269. PubMed ID: 34390192
[TBL] [Abstract][Full Text] [Related]
9. A Comparison of Topical Corticosteroids and Topical Calcineurin Inhibitors for the Treatment of Atopic Dermatitis.
Pena J; Zameza PA; Pixley JN; Remitz A; Feldman SR
J Allergy Clin Immunol Pract; 2023 May; 11(5):1347-1359. PubMed ID: 36997119
[TBL] [Abstract][Full Text] [Related]
10. Association between exposure to topical tacrolimus or pimecrolimus and cancers.
Hui RL; Lide W; Chan J; Schottinger J; Yoshinaga M; Millares M
Ann Pharmacother; 2009 Dec; 43(12):1956-63. PubMed ID: 19903860
[TBL] [Abstract][Full Text] [Related]
11. Topical calcineurin inhibitors in eczema and cancer association: A cohort study.
Cai SC; Li W; Tian EA; Allen JC; Tey HL
J Dermatolog Treat; 2016 Nov; 27(6):531-537. PubMed ID: 27049893
[TBL] [Abstract][Full Text] [Related]
12. Cancer risk with topical calcineurin inhibitors, pimecrolimus and tacrolimus, for atopic dermatitis: a systematic review and meta-analysis.
Devasenapathy N; Chu A; Wong M; Srivastava A; Ceccacci R; Lin C; MacDonald M; Wen A; Steen J; Levine M; Pyne L; Schneider L; Chu DK;
Lancet Child Adolesc Health; 2023 Jan; 7(1):13-25. PubMed ID: 36370744
[TBL] [Abstract][Full Text] [Related]
13. Stratification of atopic dermatitis patients by patterns of response to proactive therapy with topical tacrolimus: low serum IgE levels and inadequately controlled disease activity at the start of treatment predict its failure.
Kasai H; Kawasaki H; Fukushima-Nomura A; Yasuda-Sekiguchi F; Amagai M; Ebihara T; Tanese K
Ann Med; 2021 Dec; 53(1):2205-2214. PubMed ID: 34797182
[TBL] [Abstract][Full Text] [Related]
14. Systematic review on the efficacy, safety, and cost-effectiveness of topical calcineurin inhibitors in atopic dermatitis.
Chia BK; Tey HL
Dermatitis; 2015; 26(3):122-32. PubMed ID: 25984688
[TBL] [Abstract][Full Text] [Related]
15. Topical calcineurin inhibitors in the treatment of oral lichen planus: a systematic review and meta-analysis.
Sun SL; Liu JJ; Zhong B; Wang JK; Jin X; Xu H; Yin FY; Liu TN; Chen QM; Zeng X
Br J Dermatol; 2019 Dec; 181(6):1166-1176. PubMed ID: 30903622
[TBL] [Abstract][Full Text] [Related]
16. Topical calcineurin inhibitors for atopic dermatitis: review and treatment recommendations.
Carr WW
Paediatr Drugs; 2013 Aug; 15(4):303-10. PubMed ID: 23549982
[TBL] [Abstract][Full Text] [Related]
17. Retrospective markers of paediatric atopic dermatitis persistence after hospital diagnosis: A nationwide cohort study.
Thyssen JP; Corn G; Wohlfahrt J; Melbye M; Bager P
Clin Exp Allergy; 2019 Nov; 49(11):1455-1463. PubMed ID: 31464039
[TBL] [Abstract][Full Text] [Related]
18. Topical treatment utilization for patients with atopic dermatitis in the United States, and budget impact analysis of crisaborole ointment, 2.
Clark R; Bozkaya D; Levenberg M; Faulkner S; Smith TW; Gerber RA
J Med Econ; 2018 Aug; 21(8):770-777. PubMed ID: 29706103
[TBL] [Abstract][Full Text] [Related]
19. A cohort study on the risk of lymphoma and skin cancer in users of topical tacrolimus, pimecrolimus, and corticosteroids (Joint European Longitudinal Lymphoma and Skin Cancer Evaluation - JOELLE study).
Castellsague J; Kuiper JG; Pottegård A; Anveden Berglind I; Dedman D; Gutierrez L; Calingaert B; van Herk-Sukel MP; Hallas J; Sundström A; Gallagher AM; Kaye JA; Pardo C; Rothman KJ; Perez-Gutthann S
Clin Epidemiol; 2018; 10():299-310. PubMed ID: 29559812
[TBL] [Abstract][Full Text] [Related]
20. Topical calcineurin inhibitors and lymphoma risk: evidence update with implications for daily practice.
Siegfried EC; Jaworski JC; Hebert AA
Am J Clin Dermatol; 2013 Jun; 14(3):163-78. PubMed ID: 23703374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
